CVE-2015-3965 — HIGH (8.8) — White Hats Nepal

Q: How severe is CVE-2015-3965?

CVE-2015-3965 has been rated HIGH with a CVSS base score of 8.8/10. Review the CVSS metrics above for detailed severity breakdown.

Q: Is there a patch for CVE-2015-3965?

Check the references section above for vendor advisories and patch information. Affected products include: Pfizer Symbiq Infusion System Firmware, Pfizer Symbiq Infusion System.

Vulnerability Description

Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.

CVSS Score

8.8

HIGH

CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Attack Vector

NETWORK

Attack Complexity

LOW

Privileges Required

LOW

User Interaction

NONE

Scope

UNCHANGED

Confidentiality

HIGH

Integrity

HIGH

Availability

HIGH

Affected Products

Vendor	Product	Versions
Pfizer	Symbiq Infusion System Firmware	<= 3.13
Pfizer	Symbiq Infusion System	-

Related Weaknesses (CWE)

CWE-264

References

https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01Third Party AdvisoryUS Government Resource
https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01Third Party AdvisoryUS Government Resource

FAQ

What is CVE-2015-3965?

CVE-2015-3965 is a vulnerability with a CVSS score of 8.8 (HIGH). Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly ex...

How severe is CVE-2015-3965?

CVE-2015-3965 has been rated HIGH with a CVSS base score of 8.8/10. Review the CVSS metrics above for detailed severity breakdown.

Is there a patch for CVE-2015-3965?

Check the references section above for vendor advisories and patch information. Affected products include: Pfizer Symbiq Infusion System Firmware, Pfizer Symbiq Infusion System.